Chemomab Therapeutics Ltd. (CMMB) Research

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

Market snapshot

Symbol
CMMB
Price
$1.52
Day change
+1.00%
Market cap
$9.4M
P/E ratio
-1.63x
52-week range
1.35-5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • BioVie Inc. (BIVI)
  • Can-Fite BioPharma Ltd. (CANF)
  • CERo Therapeutics Holdings, Inc. (CERO)
  • PMGC Holdings Inc. (ELAB)
  • Galmed Pharmaceuticals Ltd. (GLMD)
  • InMed Pharmaceuticals Inc. (INM)
  • Kazia Therapeutics Limited (KZIA)
  • Ocean Biomedical, Inc. (OCEA)

Recent insider activity

  • Melincoff Gwen A — trade (8621 shares) on 2026-06-01
  • Mor George Adi — P-Purchase (4926 shares) on 2026-05-29
  • Mor George Adi — P-Purchase (4878 shares) on 2026-05-29
  • Mor George Adi — J-Other (31712 shares) on 2026-05-29
  • Mor George Adi — J-Other (18750 shares) on 2026-05-29

Open Chemomab Therapeutics Ltd. (CMMB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.